What is HC Wainwright's Estimate for Erasca FY2026 Earnings?

Erasca logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its FY2026 estimate to a loss of $0.54 per share from $0.51, versus the broader analyst consensus of a $0.49 loss.
  • The firm maintained its Buy rating and $22 price target on Erasca.
  • Erasca reported a quarterly loss of $0.15 per share, missing the $0.13-per-share consensus estimate.
  • Five stocks we like better than Erasca.

Erasca, Inc. (NASDAQ:ERAS - Free Report) - Equities researchers at HC Wainwright dropped their FY2026 earnings estimates for Erasca in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.54) per share for the year, down from their previous estimate of ($0.51). HC Wainwright has a "Buy" rating and a $22.00 price objective on the stock. The consensus estimate for Erasca's current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Erasca's Q4 2026 earnings at ($0.16) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.07) EPS and FY2030 earnings at ($0.88) EPS.

Erasca (NASDAQ:ERAS - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

A number of other analysts have also recently weighed in on ERAS. Guggenheim raised their target price on shares of Erasca from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, August 13th. Morgan Stanley upped their price target on Erasca from $12.00 to $21.00 and gave the company an "equal weight" rating in a report on Monday, July 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Erasca in a research report on Tuesday, September 8th. Finally, Bank of America increased their price objective on Erasca from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Friday, August 14th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.09.

Read Our Latest Stock Report on ERAS

Erasca Price Performance

ERAS stock opened at $15.11 on Tuesday. Erasca has a 12 month low of $2.52 and a 12 month high of $24.28. The firm has a market cap of $5.28 billion, a PE ratio of -15.26 and a beta of 0.68. The firm has a 50 day simple moving average of $14.94 and a 200 day simple moving average of $15.28.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wealthcare Advisory Partners LLC increased its stake in Erasca by 5.0% in the 2nd quarter. Wealthcare Advisory Partners LLC now owns 15,924 shares of the company's stock valued at $292,000 after buying an additional 756 shares during the period. Nykredit A S purchased a new stake in Erasca in the 2nd quarter worth approximately $29,000. Allworth Financial LP acquired a new stake in shares of Erasca during the 2nd quarter valued at $34,000. EverSource Wealth Advisors LLC boosted its stake in shares of Erasca by 77.8% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company's stock valued at $69,000 after buying an additional 1,859 shares during the period. Finally, ProShare Advisors LLC grew its holdings in shares of Erasca by 9.3% during the 3rd quarter. ProShare Advisors LLC now owns 39,799 shares of the company's stock valued at $583,000 after acquiring an additional 3,391 shares in the last quarter. 67.78% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Erasca

Here are a few of the latest headlines about ERAS:

  • Positive Sentiment: Erasca will host a November 20 investor event to discuss updated Phase 1 results for ERAS-0015. The company has reported early favorable safety and tolerability, along with partial responses in multiple tumor types, including at low doses. Further clinical details could be a catalyst, though these are preliminary findings. Erasca Announces Virtual Investor Event
  • Positive Sentiment: HC Wainwright retained its Buy rating and $22 price target. The firm’s outlook may help temper concerns about the company’s near-term losses.
  • Negative Sentiment: HC Wainwright lowered its loss-per-share forecasts for 2026 through 2030, including FY2027 from $0.58 to $0.90 and FY2029 from $0.70 to $1.07. The revisions suggest greater anticipated losses and could weigh on sentiment, despite the continued Buy rating.

About Erasca

(Get Free Report)

Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company's pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.

Featured Articles

Earnings History and Estimates for Erasca (NASDAQ:ERAS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Erasca Right Now?

Before you consider Erasca, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.

While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines